Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thiotepa-Fludarabine-Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from unrelated donors in patients with AML relapsing from prior allogeneic HSCT - TFT 2 Tx

Next Previous
Trial Profile

Thiotepa-Fludarabine-Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from unrelated donors in patients with AML relapsing from prior allogeneic HSCT - TFT 2 Tx

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; Thiotepa (Primary) ; Treosulfan (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms TFT 2 Tx

Most Recent Events

  • 18 Aug 2022 Results published in the Bone Marrow Transplantation
  • 30 Apr 2020 Status changed from active, no longer recruiting to completed.
  • 04 Dec 2018 Primary endpoint (To assess the probability of disease-free survival, defined as being alive and free of relapse at 1 year after 2nd allogeneic PBSCT from unrelated donors after a uniform intensive-RIC conditioning with the TFT regimen and defined GvHD prophylaxis) has been met, according to the results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top